FAQs
What is the average life expectancy for stage 4 kidney cancer spread to the lungs?
The average 5-year survival rate for stage 4 kidney cancer with lung metastases is approximately 18%. Median survival ranges from about 5-9 months without treatment to 16-22 months with modern targeted therapies and immunotherapy.
How do treatments affect survival in stage 4 kidney cancer with lung metastases?
Targeted therapies and immunotherapy combinations can significantly extend median survival to around 16-22 months, and clinical trials may push this further up to 24-30 months, compared to 5-9 months for no treatment.
What symptoms are common when kidney cancer spreads to the lungs?
Common symptoms include persistent cough, shortness of breath, fatigue, weight loss, and sometimes bone pain if cancer has spread beyond the lungs.
What factors influence prognosis in stage 4 kidney cancer?
Prognosis depends on tumor subtype, molecular markers, patient health status, risk group classification (IMDC), and whether other organs beyond the lungs are affected.
When should hospice care be considered for patients with stage 4 kidney cancer?
Hospice is typically considered when life expectancy drops below six months or symptoms become difficult to manage, focusing on comfort and quality of life.
